Eesti - eesti - Ravimiamet

actavis group ptc ehf. - losartaan - õhukese polümeerikattega tablett - 100mg 10tk; 100mg 15tk; 100mg 210tk; 100mg 21tk; 100mg 7tk; 100mg 250tk; 100mg 14tk; 100mg 50tk; 100mg 28tk; 100mg 100tk; 100mg 20tk; 100mg 280tk; 100mg 90tk; 100mg 98tk; 100mg 56tk

Eesti - eesti - Ravimiamet

krka, d.d., novo mesto - losartaan - õhukese polümeerikattega tablett - 50mg 28tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - valsartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 160mg+25mg 14tk; 160mg+25mg 30tk; 160mg+25mg 50tk; 160mg+25mg 10tk; 160mg+25mg 60tk; 160mg+25mg 84tk; 160mg+25mg 28tk; 160mg+25mg 56tk; 160mg+25mg 7tk; 160mg+25mg 98tk; 160mg+25mg 100tk; 160mg+25mg 20tk

Eesti - eesti - Ravimiamet

viatris healthcare limited - klindamütsiin+tretinoiin - geel - 10mg+0,25mg 1g 60g 1tk

Eesti - eesti - Ravimiamet

accord healthcare b.v. - losartaan - õhukese polümeerikattega tablett - 100mg 90tk; 100mg 250tk; 100mg 21tk; 100mg 1000tk; 100mg 28tk; 100mg 98tk; 100mg 30tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - losartaan - õhukese polümeerikattega tablett - 50mg 7tk; 50mg 280tk; 50mg 28tk; 50mg 30tk; 50mg 21tk; 50mg 15tk; 50mg 56tk; 50mg 14tk

Eesti - eesti - Ravimiamet

zentiva k.s. - losartaan - õhukese polümeerikattega tablett - 100mg 60tk; 100mg 30tk; 100mg 90tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bayer ag - larotrectinib sulfate - kõhu kasvajaid - antineoplastilised ained - vitrakvi nagu monotherapy on näidustatud ravi täiskasvanud ja pediaatriliste patsientide tahkete kasvajate, et kuvada neurotroofse retseptori türosiini kinase (ntrk) geen fusion,kes on haigus, mis on lokaalselt kaugelearenenud, metastaatilise või kui kirurgiline resektsioon tõenäoliselt põhjustada haigestumist, andwho on rahuldavat ravi valikud.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - ravimid hingamisteede obstruktiivsete haiguste, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastilised ained - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.